Get the Stockscreener App
2.39
2.45%
-0.06
After Hours:
2.36
-0.03
-1.26%
Gossamer Bio Inc stock is traded at $2.39, with a volume of 2.42M.
It is down -2.45% in the last 24 hours and down -7.00% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
See More
Previous Close:
$2.45
Open:
$2.49
24h Volume:
2.42M
Relative Volume:
0.66
Market Cap:
$543.44M
Revenue:
-
Net Income/Loss:
$-179.82M
P/E Ratio:
-1.797
EPS:
-1.33
Net Cash Flow:
$-159.16M
1W Performance:
+0.00%
1M Performance:
-7.00%
6M Performance:
+102.54%
1Y Performance:
+173.55%
1-Day Range:
$2.35
$2.49
1-Week Range:
$2.2808
$2.52
52-Week Range:
$0.6617
$3.60
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
2.39 | 560.76M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Will Gossamer Bio Inc. (4GB) stock keep raising dividendsPortfolio Risk Summary & Stock Portfolio Risk Management - newser.com
Gossamer Bio Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Why Gossamer Bio Inc. (4GB) stock could outperform next yearWeekly Profit Recap & Free Long-Term Investment Growth Plans - newser.com
Is Gossamer Bio Inc. stock affected by interest rate hikes2025 Historical Comparison & Weekly Top Gainers Trade List - newser.com
Why retail investors favor Gossamer Bio Inc. stock2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - newser.com
Is now a turning point for Gossamer Bio Inc.July 2025 Big Picture & Trade Opportunity Analysis - newser.com
Strategies to average down on Gossamer Bio Inc.2025 Breakouts & Breakdowns & Risk Controlled Stock Alerts - newser.com
What Fibonacci levels say about Gossamer Bio Inc. reboundJuly 2025 Fed Impact & Expert Approved Momentum Trade Ideas - newser.com
What valuation multiples suggest for Gossamer Bio Inc. stock2025 Volatility Report & AI Powered Buy/Sell Recommendations - newser.com
What Wall Street predicts for Gossamer Bio Inc. stock price2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Will Gossamer Bio Inc. stock recover faster than marketQuarterly Trade Summary & Fast Moving Stock Watchlists - newser.com
Will Gossamer Bio Inc. (4GB) stock issue positive guidancePortfolio Return Report & Growth-Oriented Investment Plans - newser.com
Can momentum traders help lift Gossamer Bio Inc.2025 Market Outlook & Capital Efficient Trade Techniques - newser.com
Is Gossamer Bio Inc. (4GB) stock nearing a technical breakoutMarket Risk Report & Free High Accuracy Swing Entry Alerts - newser.com
Is Gossamer Bio Inc. (4GB) stock supported by strong fundamentals2025 Volatility Report & Stepwise Swing Trade Plans - newser.com
Why millennials buy Gossamer Bio Inc. (4GB) stockQuarterly Profit Review & Real-Time Buy Signal Alerts - newser.com
Ranking Gossamer Bio Inc. among high performing stocks via toolsEarnings Beat & High Accuracy Buy Signal Tips - newser.com
How to use Fibonacci retracement on Gossamer Bio Inc.Product Launch & Weekly High Conviction Ideas - newser.com
Institutional Investors Control 62% of Gossamer Bio, Inc. (NASDAQ:GOSS) and Were Rewarded Last Week After Stock Increased 16% - 富途牛牛
Published on: 2025-10-31 05:26:53 - newser.com
Gossamer Bio (GOSS) to Release Quarterly Earnings on Thursday - MarketBeat
Does Gossamer Bio Inc. show high probability of reboundOptions Play & Free Community Supported Trade Ideas - newser.com
Using portfolio simulators with Gossamer Bio Inc. includedWeekly Loss Report & Free Fast Gain Swing Trade Alerts - newser.com
Why Gossamer Bio Inc. stock remains undervaluedJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):